Abstract
Biomarker testing, where a biochemical marker is used to predict the presence or absence of a disease in a subject, is an essential tool in public health screening. For many diseases, related biomarkers may have a wide range of concentration among subjects, particularly among the disease positive subjects. Furthermore, biomarker levels may fluctuate based on external or subject-specific factors. These sources of variability can increase the likelihood of subject misclassification based on a biomarker test. We study the minimization of the subject misclassification cost for public health screening of non-infectious diseases, considering regret and expectation-based objectives, and derive various key structural properties of optimal screening policies. Our case study of newborn screening for cystic fibrosis, based on real data from North Carolina, indicates that substantial reductions in classification errors can be achieved through the use of the proposed optimization-based models over current practices.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
